Literature DB >> 2386375

Comparative in vitro activity of cefixime against Haemophilus influenzae isolates, including ampicillin-resistant, non-beta-lactamase-producing isolates, from pediatric patients.

J E Mortensen1, S L Himes.   

Abstract

The in vitro activity of cefixime was comparatively tested against 232 non-type b and 102 type b isolates of Haemophilus influenzae derived from clinical specimens of pediatric patients, including 10 non-type b strains that did not produce beta-lactamase and demonstrated resistance to ampicillin. Cefixime was active against the ampicillin-susceptible and ampicillin-resistant, beta-lactamase-producing isolates; however, its activity against some non-beta-lactamase-producing, ampicillin-resistant isolates appeared to be limited.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2386375      PMCID: PMC176002          DOI: 10.1128/AAC.34.7.1456

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  18 in total

1.  Ampicillin-resistant Haemophilus influenzae type B infection.

Authors:  M O Tomeh; S E Starr; J E McGowan; P M Terry; A J Nahmias
Journal:  JAMA       Date:  1974-07-15       Impact factor: 56.272

2.  Haemophilus influenzae type B resistant to ampicillin. A report of two cases.

Authors:  W Khan; S Ross; W Rodriguez; G Controni; A K Saz
Journal:  JAMA       Date:  1974-07-15       Impact factor: 56.272

3.  In vitro activities and targets of three cephem antibiotics against Haemophilus influenzae.

Authors:  P M Mendelman; L L Henritzy; D O Chaffin; K Lent; A L Smith; T L Stull; E A Wiley
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

4.  Comparable evaluation of orally active beta-lactam compounds in ampicillin-resistant gram-positive and gram-negative rods: role of beta-lactamases on resistance.

Authors:  W Cullmann; W Dick; M Stieglitz; W Opferkuch
Journal:  Chemotherapy       Date:  1988       Impact factor: 2.544

5.  Antibacterial activities of cefpodoxime, cefixime, and ceftriaxone.

Authors:  C C Knapp; J Sierra-Madero; J A Washington
Journal:  Antimicrob Agents Chemother       Date:  1988-12       Impact factor: 5.191

6.  In vitro and in vivo antibacterial properties of FK 027, a new orally active cephem antibiotic.

Authors:  T Kamimura; H Kojo; Y Matsumoto; Y Mine; S Goto; S Kuwahara
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

7.  Antibiotic susceptibility of blood and cerebrospinal fluid isolates of Haemophilus influenzae.

Authors:  R M Bannatyne; S Toma; R Cheung; D Hodge
Journal:  J Antimicrob Chemother       Date:  1985-02       Impact factor: 5.790

8.  Characterization of non-beta-lactamase-mediated ampicillin resistance in Haemophilus influenzae.

Authors:  P M Mendelman; D O Chaffin; T L Stull; C E Rubens; K D Mack; A L Smith
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

9.  National collaborative study of the prevalence of antimicrobial resistance among clinical isolates of Haemophilus influenzae.

Authors:  G V Doern; J H Jorgensen; C Thornsberry; D A Preston; T Tubert; J S Redding; L A Maher
Journal:  Antimicrob Agents Chemother       Date:  1988-02       Impact factor: 5.191

10.  In vitro activity of cefixime (CL284635) and other antimicrobial agents against Haemophilus isolates from pediatric patients.

Authors:  A Kumar; K J Kelly
Journal:  Chemotherapy       Date:  1988       Impact factor: 2.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.